Skip to main content

Table 2 Any a and type-specific concordance b between high-risk human papillomavirus cervical DNA positivity and seropositivity, Santiago, Chile, 2001

From: Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile

HPV DNA infection

HPV seronegative n (%)

HPV seropositive n (%)

OR of seropositivity for corresponding type (95% CI)

At woman level (n = 95)

   

 HR-HPV other than HPV 16

51 (72.9)

19 (27.1)

 

 HPV 16

17 (68.0)

8 (32.0)

1.3 (0.5-3.4)

 HR-HPV other than HPV 18

74 (83.1)

15 (16.9)

 

 HPV 18

5 (83.3)

1 (16.7)

1.0 (0.1-9.1)

 HR-HPV other than HPV 31

73 (86.9)

11 (13.1)

 

 HPV 31

8 (72.7)

3 (27.3)

2.5 (0.6-10.8)

 HR-HPV other than HPV 33

84 (91.3)

8 (8.7)

 

 HPV 33

2 (66.7)

1 (33.3)

5.3 (0.4-64.4)

 HR-HPV other than HPV 35

74 (80.4)

18 (19.6)

 

 HPV 35

1 (33.3)

2 (66.7)

8.2 (0.7-95.8)

 HR-HPV other than HPV 45

71 (80.7)

17 (19.3)

 

 HPV 45

6 (85.7)

1 (14.3)

0.7 (0.1-6.2)

 HR-HPV other than HPV 52

76 (86.4)

12 (13.6)

 

 HPV 52

7 (100)

0

0

 HR-HPV other than HPV 58

79 (96.3)

3 (3.7)

 

 HPV 58

12 (92.3)

1 (7.7)

2.2 (0.2-22.9)

At infection level (n = 760)

   

 Positive to different HR-HPV

582 (85.0)

103 (15.0)

 

 Positive to same HR-HPV

58 (77.3)

17 (22.7)

1.7 (1.1-2.5)

  1. aAny HPV refers to HPV types 16, 18, 31, 33, 35, 45, 52, and 58.
  2. bOnly among HPV DNA positive infections.
  3. Bold: statistically significant results (p-value < 0.05).
  4. HR: high-risk, HPV: human papillomavirus, OR: odds ratio, CI: confidence interval.